Japan· JP-2639700Q1012
ナジフロキサシン
A nadifloxacin product containing ナジフロキサシン, registered in Japan, on the national reimbursement list. The same ATC class is registered in 2 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Nadifloxacin is registered in 2 of 19 countries.
Countries holding a registration under ATC D10AF05 (nadifloxacin), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
Nadifloxacin · ATC D10AF05
2 / 19 countries
- Germany
- Japan
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ナジフロキサシン
- Manufacturer
- —
- Country
- Japan (JP)
- ATC code
- D10AF05
- ATC class
- Nadifloxacin
- Defined daily dose
- 20 mg, T
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- October 2, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under D10AF05
Nadifloxacin, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2c9604e0-10f7-4311-bf73-08b971d37515 GET /v1/drugs/2c9604e0-10f7-4311-bf73-08b971d37515?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１％１ｍＬ",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2639700Q1012",
"category": "外用薬",
"price_yen": 17,
"generic_name": "ナジフロキサシン",
"product_name_jp": null,
"therapeutic_class": "2639",
"transitional_expiry": null
}See everything about nadifloxacin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.